NASDAQ:SRRK Scholar Rock - SRRK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Scholar Rock Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. $12.37 +0.14 (+1.14%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$11.83▼$12.9150-Day Range$7.51▼$12.7252-Week Range$4.32▼$21.17Volume289,223 shsAverage Volume354,486 shsMarket Capitalization$639.03 millionP/E RatioN/ADividend YieldN/APrice Target$25.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Scholar Rock MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside107.5% Upside$25.67 Price TargetShort InterestBearish5.32% of Shares Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$455,061 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector495th out of 1,030 stocksBiological Products, Except Diagnostic Industry76th out of 169 stocks 3.5 Analyst's Opinion Consensus RatingScholar Rock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.67, Scholar Rock has a forecasted upside of 107.5% from its current price of $12.37.Amount of Analyst CoverageScholar Rock has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.32% of the outstanding shares of Scholar Rock have been sold short.Short Interest Ratio / Days to CoverScholar Rock has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Scholar Rock has recently increased by 7.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldScholar Rock does not currently pay a dividend.Dividend GrowthScholar Rock does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreScholar Rock has received a 74.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Scholar Rock is -0.78. Previous Next 1.9 News and Social Media Coverage News SentimentScholar Rock has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Scholar Rock this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SRRK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows1 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scholar Rock insiders have bought 4,287.82% more of their company's stock than they have sold. Specifically, they have bought $455,061.00 in company stock and sold $10,371.00 in company stock.Percentage Held by InsidersOnly 2.05% of the stock of Scholar Rock is held by insiders.Percentage Held by Institutions91.63% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Scholar Rock are expected to remain at ($2.37) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scholar Rock is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scholar Rock is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScholar Rock has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Scholar Rock (NASDAQ:SRRK) StockScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Read More Receive SRRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter. Email Address SRRK Stock News HeadlinesJanuary 29, 2023 | americanbankingnews.comScholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from BrokeragesJanuary 26, 2023 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Trading Up 4.2%February 2, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.January 11, 2023 | seekingalpha.comScholar Rock Holding (SRRK) presents at 41st Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 11, 2023 | nypost.comCalling all NY high school students: Enter the New York Post Scholars ContestJanuary 9, 2023 | finance.yahoo.comScholar Rock Provides Corporate Update and Highlights Priorities for 2023January 3, 2023 | finance.yahoo.comScholar Rock to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNovember 16, 2022 | finance.yahoo.comScholar Rock Holding Third Quarter 2022 Earnings: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)February 2, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.November 14, 2022 | finance.yahoo.comScholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business ProgressNovember 10, 2022 | finance.yahoo.comRecent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of EfficacyNovember 9, 2022 | finance.yahoo.comScholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical OfficerOctober 30, 2022 | msn.comOver $1 Million Bet On Scholar Rock Holding? 3 Stocks Insiders Are BuyingOctober 28, 2022 | benzinga.com1.05M Reasons To Be Bullish On Scholar Rock Holding StockOctober 22, 2022 | finance.yahoo.comNew Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMAOctober 20, 2022 | seekingalpha.comScholar Rock: OLE Data In SMA Coupled With New CEO Make It A BuyOctober 18, 2022 | nasdaq.comScholar Rock Holding (NASDAQ:SRRK) shareholders have endured a 73% loss from investing in the stock a year agoOctober 6, 2022 | finance.yahoo.comScholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual MeetingOctober 4, 2022 | finance.yahoo.comScholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular AtrophyOctober 3, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)September 23, 2022 | finance.yahoo.comScholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 21, 2022 | seekingalpha.comJay Backstrom is the new CEO at Scholar RockSeptember 20, 2022 | finance.yahoo.comScholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive OfficerSeptember 19, 2022 | finance.yahoo.comAnalyst Builds Bullish Case For This Neuromuscular Company, Sees 200% UpsideSeptember 19, 2022 | markets.businessinsider.comExpert Ratings for Scholar Rock HoldingSeptember 16, 2022 | finance.yahoo.comScholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx SummitSeptember 4, 2022 | finance.yahoo.comInvestors in Scholar Rock Holding (NASDAQ:SRRK) have unfortunately lost 75% over the last yearSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter. Email Address SRRK Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRK CUSIPN/A CIK1727196 Webwww.scholarrock.com Phone(857) 259-3860Fax866-493-4935Employees145Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.67 High Stock Price Forecast$33.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+107.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,800,000.00 Net MarginsN/A Pretax Margin-352.19% Return on Equity-54.30% Return on Assets-37.88% Debt Debt-to-Equity Ratio0.17 Current Ratio10.60 Quick Ratio10.60 Sales & Book Value Annual Sales$18.82 million Price / Sales33.96 Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book2.52Miscellaneous Outstanding Shares51,660,000Free Float50,604,000Market Cap$639.03 million OptionableNot Optionable Beta0.72 Key ExecutivesMr. Edward H. Myles M.B.A. (Age 51)MBA, CFO, COO & Treasurer Comp: $615.87kDr. Jay T. Backstrom M.D. (Age 67)M.P.H., Pres, CEO & Director Ms. Catherine HuVP of Investor Relations & Corp. CommunicationsMs. Junlin Ho J.D. (Age 44)Gen. Counsel & Corp. Sec. Ms. Caryn Parlavecchio (Age 51)Chief HR Officer Ms. Lisa Amaya PriceSr. VP of HRDr. George G. Nomikos M.D.Ph.D., Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic AreaMs. Erin Moore (Age 48)Sr. VP of Fin. Mr. Ryan IarrobinoSr. VP of Clinical Devel. & OperationsDr. Jing L. Marantz M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsImmaticsNASDAQ:IMTXFate TherapeuticsNASDAQ:FATEPoseida TherapeuticsNASDAQ:PSTXHilleVaxNASDAQ:HLVXCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCSold 2,258 shares on 1/27/2023Ownership: 0.087%Public Equities L.P. InvusSold 1,094 sharesTotal: $10,371.12 ($9.48/share)Public Equities L.P. InvusBought 48,774 shares on 1/5/2023Total: $455,061.42 ($9.33/share)Bank of New York Mellon CorpBought 5,544 shares on 12/8/2022Ownership: 0.033%Alpha Paradigm Partners LLCBought 7,272 shares on 11/16/2022Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions SRRK Stock - Frequently Asked Questions Should I buy or sell Scholar Rock stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares. View SRRK analyst ratings or view top-rated stocks. What is Scholar Rock's stock price forecast for 2023? 5 equities research analysts have issued 12-month price objectives for Scholar Rock's shares. Their SRRK share price forecasts range from $19.00 to $33.00. On average, they expect the company's stock price to reach $25.67 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price. View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts. How have SRRK shares performed in 2023? Scholar Rock's stock was trading at $9.05 on January 1st, 2023. Since then, SRRK stock has increased by 38.6% and is now trading at $12.54. View the best growth stocks for 2023 here. When is Scholar Rock's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023. View our SRRK earnings forecast. How were Scholar Rock's earnings last quarter? Scholar Rock Holding Co. (NASDAQ:SRRK) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.13. What other stocks do shareholders of Scholar Rock own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA). When did Scholar Rock IPO? (SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Scholar Rock's stock symbol? Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK." Who are Scholar Rock's major shareholders? Scholar Rock's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman and Public Equities LP Invus. View institutional ownership trends. How do I buy shares of Scholar Rock? Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Scholar Rock's stock price today? One share of SRRK stock can currently be purchased for approximately $12.54. How much money does Scholar Rock make? Scholar Rock (NASDAQ:SRRK) has a market capitalization of $647.82 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. How many employees does Scholar Rock have? The company employs 145 workers across the globe. How can I contact Scholar Rock? Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935. This page (NASDAQ:SRRK) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.